December 22, 2025

FDA Approves New Treatment for Lung Fibrosis

Nerandomilast becomes first preferential PDE4B inhibitor approved for PPF, slowing FVC decline in phase 3 trial

Conexiant

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

December 03, 2025

Ranitidine’s return 'unlikely to provide greater clinical benefit'

New formulation incorporates stronger manufacturing controls and stability measures to prevent NDMA from forming.

Conexiant

November 26, 2025

FDA Grants Accelerated Approval of Voyxact

The subcutaneous injection offers a new option for adults at risk of progression to kidney failure.

Conexiant

November 17, 2025

‘Patent Dance’ Delays Biosimilars Despite FDA Shift

The FDA moves to speed biosimilar approvals, but rising patent barriers may still delay lower-cost alternatives.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 20, 2025

Obinutuzumab Wins FDA Nod for Lupus Nephritis

Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.

Conexiant

September 29, 2025

FDA Expands Options for Pediatric Psoriasis, PsA

The FDA has approved the first IL-23 inhibitor for pediatric patients with plaque psoriasis and psoriatic arthritis.

Conexiant